ERBB2 and breast cancer: However, in approximately 20% of breast cancer cases, HER2 is overexpressed, leading to constitutive activation, uncontrolled cell proliferation, migration and invasion, being frequently associated with high recurrence rates and poor prognosis [5,8,9,10].